Soluble CD30 measured after lung transplantation does not predict bronchiolitis obliterans syndrome in a tacrolimus/mycophenolate mofetil-based immunosuppressive regimen
Kwakkel - van Erp, J.M.; Otten, H.G.; Paantjens, A.W.M.; Kessel, D.A.; van Ginkel, W.G.J.; van den Bosch, J.M.M.; van de Graaf, E.A.
(2008) Journal of Heart and Lung Transplantation, volume 27, issue 10, pp. 1172 - 1175
(Article)
Abstract
BACKGROUND: The purpose of this study was to determine the utility of post-transplant serum soluble CD30 levels as a biomarker for the development of the bronchiolitis obliterans syndrome (BOS) after lung transplantation during a tacrolimus/mycophenolate mofetil-based regimen. METHODS: Soluble CD30 (sCD30) concentrations were measured prior to transplantation and in 175
... read more
samples taken after transplantation in 7 patients developing BOS and 7 non-BOS patients closely matched for age, underlying diseases, follow-up and gender. RESULTS: High pre-transplant sCD30 levels dropped significantly after lung transplantation, but in the post-transplant samples no differences could be detected between patients developing BOS or not, and no changes were found prior to or during the development of BOS. CONCLUSIONS: After transplantation, sCD30 levels are consistently suppressed, but BOS is not prevented, indicating that sCD30 cannot be used as a biomarker to predict BOS after transplantation in the regimen employed.
show less
Download/Full Text
The full text of this publication is not available.
Keywords: Adult, Antigens, CD, Biomarkers, Bronchiolitis Obliterans, Emphysema, Female, Graft Survival, Humans, Immunosuppressive Agents, Informed Consent, Ki-1 Antigen, Lung Transplantation, Male, Middle Aged, Mycophenolic Acid, Postoperative Complications, Predictive Value of Tests, Pulmonary Disease, Chronic Obstructive, Tacrolimus, Case Reports, Journal Article
ISSN: 1053-2498
Publisher: Elsevier USA
(Peer reviewed)